JP2021500049A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500049A5
JP2021500049A5 JP2020523011A JP2020523011A JP2021500049A5 JP 2021500049 A5 JP2021500049 A5 JP 2021500049A5 JP 2020523011 A JP2020523011 A JP 2020523011A JP 2020523011 A JP2020523011 A JP 2020523011A JP 2021500049 A5 JP2021500049 A5 JP 2021500049A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
isolated nucleic
vector
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523011A
Other languages
English (en)
Japanese (ja)
Other versions
JP7413256B2 (ja
JP2021500049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/057187 external-priority patent/WO2019084068A1/en
Publication of JP2021500049A publication Critical patent/JP2021500049A/ja
Publication of JP2021500049A5 publication Critical patent/JP2021500049A5/ja
Priority to JP2023220260A priority Critical patent/JP2024045131A/ja
Application granted granted Critical
Publication of JP7413256B2 publication Critical patent/JP7413256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523011A 2017-10-23 2018-10-23 神経変性疾患の遺伝子治療 Active JP7413256B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023220260A JP2024045131A (ja) 2017-10-23 2023-12-27 神経変性疾患の遺伝子治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762575795P 2017-10-23 2017-10-23
US62/575,795 2017-10-23
US201862742723P 2018-10-08 2018-10-08
US62/742,723 2018-10-08
PCT/US2018/057187 WO2019084068A1 (en) 2017-10-23 2018-10-23 GENE THERAPIES FOR NEURODEGENERATIVE DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023220260A Division JP2024045131A (ja) 2017-10-23 2023-12-27 神経変性疾患の遺伝子治療

Publications (3)

Publication Number Publication Date
JP2021500049A JP2021500049A (ja) 2021-01-07
JP2021500049A5 true JP2021500049A5 (cg-RX-API-DMAC7.html) 2021-11-25
JP7413256B2 JP7413256B2 (ja) 2024-01-15

Family

ID=66247008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523011A Active JP7413256B2 (ja) 2017-10-23 2018-10-23 神経変性疾患の遺伝子治療
JP2023220260A Pending JP2024045131A (ja) 2017-10-23 2023-12-27 神経変性疾患の遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023220260A Pending JP2024045131A (ja) 2017-10-23 2023-12-27 神経変性疾患の遺伝子治療

Country Status (11)

Country Link
US (1) US20210261981A1 (cg-RX-API-DMAC7.html)
EP (1) EP3701030A4 (cg-RX-API-DMAC7.html)
JP (2) JP7413256B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200075865A (cg-RX-API-DMAC7.html)
CN (2) CN113005123A (cg-RX-API-DMAC7.html)
AU (1) AU2018354195A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008033A2 (cg-RX-API-DMAC7.html)
CA (2) CA3083582A1 (cg-RX-API-DMAC7.html)
IL (2) IL274129A (cg-RX-API-DMAC7.html)
MX (1) MX2020004207A (cg-RX-API-DMAC7.html)
WO (1) WO2019084068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004005A (es) 2017-10-03 2020-10-05 Prevail Therapeutics Inc Terapias genicas para los trastornos lisosomales.
EP3692158A4 (en) 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
CN111542549A (zh) 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
EP3762505A4 (en) * 2018-03-09 2021-12-01 Avrobio, Inc. COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE
HRP20251506T1 (hr) 2019-04-10 2026-01-02 Prevail Therapeutics, Inc. Genska terapija za lizosomske poremećaje
JP7664848B2 (ja) 2019-04-10 2025-04-18 プリベイル セラピューティクス,インコーポレーテッド リソソーム障害のための遺伝子療法
EP4048794A4 (en) * 2019-10-22 2024-04-17 Applied Genetic Technologies Corporation Triple function adeno-associated virus (aav) vectors for the treatment of c9orf72 associated diseases
EP4100527A2 (en) * 2020-02-07 2022-12-14 Maze Therapeutics, Inc. Compositions and methods for treating neurodegenerative diseases
US20240294906A1 (en) * 2020-07-29 2024-09-05 Alnylam Pharmaceuticals, Inc. Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases
JP2023545830A (ja) 2020-10-15 2023-10-31 プリベイル セラピューティクス,インコーポレーテッド 組換えアデノ随伴ウイルス組成物及びその生産方法
WO2022081985A1 (en) 2020-10-15 2022-04-21 Prevail Therapeutics, Inc. Assay for measuring potency of gene therapy drug product
TWI910261B (zh) 2020-11-06 2026-01-01 日商住友製藥股份有限公司 Rps25基因之表現及/或功能調節劑
JP2024505081A (ja) 2021-01-28 2024-02-02 エイブレイン 神経変性疾患を治療するための遺伝子療法
JP2024508635A (ja) 2021-01-28 2024-02-28 エイブレイン 神経変性疾患を治療するための遺伝子療法
KR102707250B1 (ko) 2021-10-28 2024-09-13 한국해양과학기술원 신규 화합물 및 이를 유효성분으로 포함하는 신경염증성 뇌질환 예방 또는 치료용 조성물
TW202340467A (zh) * 2022-01-10 2023-10-16 賓州大學委員會 有用於治療c9orf72介導之病症之組成物及方法
JP2025516136A (ja) 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
JPWO2024257847A1 (cg-RX-API-DMAC7.html) 2023-06-16 2024-12-19
JP7684628B1 (ja) 2024-03-21 2025-05-28 日本製鉄株式会社 自動車リアモジュール
WO2026064802A1 (en) * 2024-09-23 2026-03-26 The General Hospital Corporation Gene therapy platform to restore gabaergic inhibition and improve cognition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
CA2596588C (en) * 2005-01-31 2017-06-27 University Of Iowa Research Foundation Nucleic acid silencing of huntington's disease gene
JP5559185B2 (ja) * 2008-11-11 2014-07-23 オックスフォード バイオメディカ(ユーケー)リミテッド 方法
US20110142789A1 (en) * 2009-12-10 2011-06-16 The Trustees Of The University Of Pennsylvania Compositions and Methods for the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達
PT2841578T (pt) * 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
HK1214521A1 (zh) * 2012-11-05 2016-07-29 Genzyme Corporation 用於治療蛋白質病的組合物和方法
US20140271550A1 (en) * 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
MY192689A (en) * 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
JP6756700B2 (ja) * 2014-03-18 2020-09-16 ユニバーシティ オブ マサチューセッツ 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
SI3119888T1 (sl) * 2014-03-19 2021-11-30 Ionis Pharmaceuticals, Inc. Sestavki za moduliranje izražanja ataksina 2
WO2015153760A2 (en) * 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
WO2016024205A1 (en) * 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
CN114717264A (zh) * 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3285788B1 (en) * 2015-04-23 2024-12-18 University of Massachusetts Modulation of aav vector transgene expression
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
CA3016314A1 (en) * 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
MX381216B (es) * 2016-09-30 2025-03-12 Regeneron Pharma Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
WO2020053258A1 (en) * 2018-09-12 2020-03-19 Uniqure Ip B.V. Rnai induced c9orf72 suppression for the treatment of als/ftd

Similar Documents

Publication Publication Date Title
US11060113B2 (en) Gene therapies for lysosomal disorders
JP2024045131A (ja) 神経変性疾患の遺伝子治療
JP7616995B2 (ja) 神経変性疾患のための遺伝子治療
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP2020537542A5 (cg-RX-API-DMAC7.html)
JP2020019772A5 (cg-RX-API-DMAC7.html)
JP2020537543A5 (cg-RX-API-DMAC7.html)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
CA3249551A1 (en) AAV Capsid Variants and Their Uses
JP2017510298A5 (cg-RX-API-DMAC7.html)
JP2020532981A5 (cg-RX-API-DMAC7.html)
JP2020513831A (ja) MeCP2発現カセット
JP2022511453A5 (cg-RX-API-DMAC7.html)
JP2023537980A5 (cg-RX-API-DMAC7.html)
JP2023501897A5 (cg-RX-API-DMAC7.html)
JP2023553005A5 (cg-RX-API-DMAC7.html)
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
JP2021534794A5 (cg-RX-API-DMAC7.html)
US20200283800A1 (en) Gene therapies for neurodegenerative diseases
JP2023551254A5 (cg-RX-API-DMAC7.html)
JP2025512709A5 (cg-RX-API-DMAC7.html)
HK40015201B (en) Shrna expression cassette, polynucleotide sequence carrying same, and application thereof